Skip to content
STAT: psychedelics· Adam Feuerstein·AI score62

Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront

STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley

AI summary

Eli Lilly is acquiring AtaiBeckley, a developer of psychedelic treatments for mental health conditions.

Key facts

Organisation
AtaiBeckley
Jurisdiction
United States
Source
STAT: psychedelics (statnews.com)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: STAT: psychedelics · statnews.com

Connected to

Organisation
AtaiBeckley
Jurisdiction
United States

Other recent items on these topics